pmid 26048277
Pazdur paper

pmid 20728210
Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced
gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomized
controlled trial. Lancet 376(9742), 687–697 (2010).

pmid 19581909
Chen, H. X., Cleck, J. Adverse effects of anticancer agents that target the VEGF pathway
N. Nat. Rev. Clin. Oncol. 2009, 6, 465–477

pmid 18172173
Cunningham D, Starling N, Rao S et al. Upper gastrointestinal clinical studies group of
the National Cancer Research Institute of the United Kingdom. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36–46 (2008).

pmid 17591804
De Vita, F. Giuliani G. Galizia, C. Belli G. Aurilio, G. et al. Neo-adjuvant and adjuvant
chemotherapy of gastric cancer. Annals of Oncology 18 (Supplement 6): vi120–vi123,
2007

pmid 9827707
Devessa S., Blot W, Fraumeni J. Changing patterns in the incidence of esophageal and
gastric carcinoma in the U.S. Cancer 1998; 83:2049

pmid 18596824
Ellis L. and Hicklin D. VEGF targeted therapy: mechanisms of anti-tumor activity.
Nature Reviews Cancer, 2008 , August V8, 579-591

pmid 24332238
Ford H. Cougar -02: A randomized Phase 3 study of docetaxel vs. active symptom
control in advanced esophagogastric adenocarcinoma. Lancet Oncology, 2014, V15: 78-
87.

pmid 19482548
Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer
treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10: 559–68

pmid 8559202
Hinchey J., Chaves C., Appignani B., Breen J., Pao L. et al. A reversible posterior
leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494-500.

pmid 20006922
Izzedine H., Massard C., Spano JP., Goldwasser F., Khayat D. et al. VEGF signaling
inhibition-induced proteinuria: Mechanisms, significance and management. Eur. J. of
Cancer 2010, 46:439-448

pmid 15169807
Johnson D., Fehrenbacher L., Novotny W., Herbst R., Nemunaitis J. et al. Randomized
Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin
and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-
Small-Cell Lung Cancer. J. Clin. Oncol. 2004, V22, No 11: 2184-2191

pmid 22412140
Kang JH, Lee S, Lim DH, Park KW, Oh SY. et al. Salvage chemotherapy for pretreated
gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive
care with best supportive care alone. J Clin Oncol 30:1513-1518

pmid 19153121
Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-
fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a
randomized Phase 3 non-inferiority trial. Ann. Oncol. 20(4), 666–673 (2009).

pmid 22893596
Khorana A., Dalal M.; Lin J and Connolly G. Incidence and Predictors of Venous
Thromboembolism (VTE) Among Ambulatory High-Risk Cancer Patients Undergoing
Chemotherapy in the United States. Cancer V119 N3, Feb 1 2013 , 648-655

pmid 18282805
Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): a Phase 3 trial. Lancet Oncol. 9(3),215–221 (2008).

pmid 11376265
Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome:
evaluation with diffusion-tensor MR imaging. Radiology. 2001; 219:756–65.

pmid 21844504
Ohtsu A., Shah M., Van Cutsem E., Rha SY., Sawaki A. et al. Bevacizumab in
combination with chemotherapy as first-line therapy in advanced gastric cancer: a
randomized, double-blind, placebo-controlled Phase 3 study. J Clin Oncol V29:3968-
3976

pmid 19474114 
Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032
trials: evaluating capecitabine-based combination chemotherapy and infused 5-
fluorouracil-based combination chemotherapy for the treatment of advanced oesophagogastric
cancer. Ann. Oncol. 20(9), 1529–1534 (2009).

pmid 22375525
Price T., Shapiro D., Segelov E., Karapetis C., Pavlakis N. et al. Management of
advanced gastric cancer. Expert Rev. Gastroenterol. Hepatol. 6(2), 199–209 (2012)

pmid 18690886
Roodhart J., Marlies H. Langenberg H., Witteveen L., Voest E. The Molecular Basis of
Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology, 2008, 3, 132-143.

pmid 17167137
Sandler A., Gray R., Perry M., Brahmer J., Schiller J. Paclitaxel–Carboplatin Alone or
with Bevacizumab for Non–Small-Cell Lung Cancer. N Engl J Med 2006; 355:2542-
2550.

pmid 16118771
Scappaticci F., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W. et al. Surgical
wound healing complications in metastatic colorectal cancer patients treated with
bevacizumab. J. Surg. Oncol 2005, 3:173-80.

pmid 17686822
Scappaticci F., Skillings J., Holden S., Gerber H., Miller K. et al. Arterial
thromboembolic events in patients with metastatic carcinoma treated with chemotherapy
and bevacizumab. J. Natl. Cancer Inst. 2007 Aug 15; 99(16):1232-9.

pmid 17114652
Shah M., Ramanathan R., Ilson D., Levnor A., D’Adamo D et al. Multicenter Phase II
study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or
gastroesophageal junction adenocarcinoma. J. Clin Oncol V24 N33 November 2006
5201-5206

pmid 23335087
Siegel R., Naishadham D., Jemal A. Cancer Statistics, 2013. CA Cancer J. Clin 2013;
63:11-30 

pmid 21742485
Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A. et al. Survival advantage
for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer –
A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
European J Cancer 47 (2011) 2306:2314

pmid 22565005
Van Cutsem E, de Haas S., Kang YK, Ohtsu A, Tebbutt N. et al. Bevacizumab in
Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer:A
Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. J Clin Oncol
30:2119-2127.

pmid 17075117
Van Cutsem E, Moiseyenko VM, Tjulandin S et al. V325 study group. Phase 3 study of
docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline
therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin.
Oncol. 24(31), 4991–4997 (2006).

pmid 17356952
Wasif Saif M., Elfiky A., Salem R. Gastrointestinal Perforation Due to Bevacizumab in
Colorectal Cancer. ChBAnn als of Surgical Oncology 2007 14( 6): 1860- 1869.
 
pmid 19717092
Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced
gastric cancer? Lancet Oncol. 10(9), 903- 912 (2009).

pmid 10215831
Wijnhoven B., Siersema P., Hop W. et al Aden ocarcinoma of the distal esophagus and
gastric cardia are one clinical entity . Br. J. of Surge1y 1999; 86:529

pmid 19474114
Okines A., Nonnan A., Mc Cloud P., Kang YK, Cunningham D. Meta-analysis of the
REAL-2 and MLl 7032 trials: evaluating capecitabine -based combin ation chemotherapy
and infused 5-fluoroura cil-based combin ation chemotherapy for the treatm ent of
advanced esophago-gastric cancer. Ann Oncolo (2009) doi l0 .1093

pmid 15197201
Chau I, Nonnan AR, Cunningham D, et al. Multivariate progn ostic factor analysis in
locally advanced and metastatic esophago-gastric cancer --pooled analysis from three
multicenter, randomized, controlled trials using individual patient data .. J Clin Oncol.
2004;22( 12) :2395-2403.

pmid 9053510
Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Con e la ti on between expression
of vascular endothelial growth factor and tumor vascularity, and patient outcome in
human gastric carcinoma. J Clin Oncol. 1997;15(2):826 -832.

pmid 11978184
Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible
nitric oxide synthase and vascular endothelial growth factor in gastric precancerou s and
cancerous lesions: Cone lation with clinical feature s. BMC Cancer. 2002 ;2:8.

pmid 16344322
Jtittner S, Wissmann C, Jons T, Vieth M, Hertel J, et al. Vascular endothelial growth
factor-D and its receptor VEGFR -3: Two novel independent progn ostic markers in
gastric adenocarcinoma. J Clin Oncol. 2006;24(2):228 -240.

pmid 12131083
Karayiannakis AJ, Syrigos KN, Polychroni dis A, Zbar A, Kourakl is G, et al. Circulating
VEGF levels in the senun of gastric cancer patients: Conel ation with pathological
variables, survival, and tumor surge1y. Ann Surg. 2002;236:37-42.





